Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
Oral Capecitabine as an Alternative to IV 5-fluorouracil-Based Adjuvant Therapy for Colon Cancer: Safety Results of a Randomized, Phase III Trial
March 1, 2004